Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prantesh Jain

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Therapeutic Advances in Respiratory Disease|February 2, 2018
Role of immune-checkpoint inhibitors in lung cancerPrantesh Jain, Chhavi Jain, Vamsidhar Velcheti
The Journal of Community and Supportive Oncology|April 9, 2015
Breast cancer with brain metastases in pregnancyShweta Gupta, Prantesh Jain, Susan McDunn
Expert Review of Anticancer Therapy|November 25, 2014
Afatinib and lung cancerPrantesh Jain, Rashmi Khanal, Aakanksha Sharma, et al.
Expert Opinion on Therapeutic Targets|May 4, 2021
MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapiesMatthew Lee, Prantesh Jain, Feng Wang, et al.
Clinical Lung Cancer|February 14, 2018
Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-AnalysisMonica Khunger, Prantesh Jain, Sagar Rakshit, et al.
Cancer Letters|June 13, 2025
AI-based radiomic features predict outcomes and the added benefit of chemoimmunotherapy over chemotherapy in extensive stage small cell lung cancer: A multi-institutional studyMohammadhadi Khorrami, Pushkar Mutha, Cristian Barrera, et al.
Cancers|January 25, 2025
Phase II Study of Nanoliposomal Irinotecan (Nal-IRI) with 5-Fluorouracil and Leucovorin in Refractory Advanced High-Grade Neuroendocrine Cancer of Gastroenteropancreatic (GEP) or Unknown OriginSarbajit Mukherjee, Harsha Pattnaik, Sahithi Sonti, et al.
Journal for Immunotherapy of Cancer|October 14, 2020
Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockadePranjal Vaidya, Kaustav Bera, Pradnya D Patil, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 31, 2024
Trilaciclib use in extensive-stage small cell lung cancer (ES-SCLC): are clinical benefits seen in the real-world setting?Joseph Elijah, Prantesh Jain, Allison Holdsworth, et al.
Frontiers in Oncology|November 8, 2021
Novel Non-Invasive Radiomic Signature on CT Scans Predicts Response to Platinum-Based Chemotherapy and Is Prognostic of Overall Survival in Small Cell Lung CancerPrantesh Jain, Mohammadhadi Khorrami, Amit Gupta, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Therapeutic Advances in Respiratory Disease|February 2, 2018
Role of immune-checkpoint inhibitors in lung cancerPrantesh Jain, Chhavi Jain, Vamsidhar Velcheti
The Journal of Community and Supportive Oncology|April 9, 2015
Breast cancer with brain metastases in pregnancyShweta Gupta, Prantesh Jain, Susan McDunn
Expert Review of Anticancer Therapy|November 25, 2014
Afatinib and lung cancerPrantesh Jain, Rashmi Khanal, Aakanksha Sharma, et al.
Expert Opinion on Therapeutic Targets|May 4, 2021
MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapiesMatthew Lee, Prantesh Jain, Feng Wang, et al.
Clinical Lung Cancer|February 14, 2018
Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-AnalysisMonica Khunger, Prantesh Jain, Sagar Rakshit, et al.
Cancer Letters|June 13, 2025
AI-based radiomic features predict outcomes and the added benefit of chemoimmunotherapy over chemotherapy in extensive stage small cell lung cancer: A multi-institutional studyMohammadhadi Khorrami, Pushkar Mutha, Cristian Barrera, et al.
Cancers|January 25, 2025
Phase II Study of Nanoliposomal Irinotecan (Nal-IRI) with 5-Fluorouracil and Leucovorin in Refractory Advanced High-Grade Neuroendocrine Cancer of Gastroenteropancreatic (GEP) or Unknown OriginSarbajit Mukherjee, Harsha Pattnaik, Sahithi Sonti, et al.
Journal for Immunotherapy of Cancer|October 14, 2020
Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockadePranjal Vaidya, Kaustav Bera, Pradnya D Patil, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 31, 2024
Trilaciclib use in extensive-stage small cell lung cancer (ES-SCLC): are clinical benefits seen in the real-world setting?Joseph Elijah, Prantesh Jain, Allison Holdsworth, et al.
Frontiers in Oncology|November 8, 2021
Novel Non-Invasive Radiomic Signature on CT Scans Predicts Response to Platinum-Based Chemotherapy and Is Prognostic of Overall Survival in Small Cell Lung CancerPrantesh Jain, Mohammadhadi Khorrami, Amit Gupta, et al.
Pageof 3